NCT01530984View on ClinicalTrials.gov

Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2018

Conditions
Prostate Cancer
Interventions
DRUG

Ipilimumab

Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.

DRUG

GM-CSF

GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.

Trial Locations (1)

94115

University of California, San Francisco

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

Lawrence Fong

OTHER